Global

‡ In these countries please contact our distributor

Smith & Nephew selected for FTSE4Good index for 17th consecutive year

22 January 2018

Smith & Nephew, (LSE:SN, NYSE:SNN), the global medical technology business, is proud to announce that it has retained its membership of the FTSE4Good index following the December 2017 index review.

The FTSE4Good is the pioneering global responsible investment index, designed to identify companies that demonstrate strong environmental, social and governance (ESG) practices measured against international standards. The indexes identify companies that better manage ESG risks and are used as a basis for tracker funds, structured products and as a performance benchmark. The ESG Ratings are used by investors who wish to incorporate ESG factors into their investment decision-making processes, or as a framework for corporate engagement and stewardship.

A member of the FTSE4Good index since 2001, Smith & Nephew consistently score well across the three pillars of sustainability, (Environmental, Social and Governance) with the latest review highlighting its continued commitment towards sustainable operations.

Olivier Bohuon, Chief Executive Officer of Smith & Nephew, said:

"Improving human health is at the heart of our business. We have recognised that sustainability is part of who we are as an organisation and we cannot be successful without a core commitment to societal and environmental wellbeing. Our stated mission, supporting healthcare professionals in their daily efforts to improve the lives of their patients, wholeheartedly embraces social responsibility.”

Enquiries

Investors/ Analysts

Ingeborg Øie
+44 (0) 20 7960 2285
Smith & Nephew plc

Media

Charles Reynolds
+44 (0) 1923 477314
Smith & Nephew plc

Matt Copeman
+44 (0) 1923 477385
Smith & Nephew plc

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

Sustainability report 2016

Front cover of sustainability report 2016

A future focus. Supporting healthcare professionals for over 150 years

Read

Smith & Nephew retains FTSE4Good status

Smith & Nephew is proud to announce that it has retained its membership of the FTSE4Good index for the 16th consecutive year.